Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece
Crossref DOI link: https://doi.org/10.1007/s00296-017-3736-z
Published Online: 2017-05-18
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tzanetakos, C.
Tzioufas, A.
Goules, A.
Kourlaba, G.
Theodoratou, T.
Christou, P.
Maniadakis, N.
License valid from 2017-05-18